Organon/$OGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Organon
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
- Ticker
- $OGN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 10,000
- Headquarters
- Jersey City, United States
- Website
- www.organon.com
Organon Metrics
BasicAdvanced
$3.6B
17.33
$0.79
1.52
$0.08
0.58%
Price and volume
Market cap
$3.6B
Beta
1.52
52-week high
$13.83
52-week low
$5.69
Average daily volume
2.4M
Dividend rate
$0.08
Financial strength
Current ratio
1.954
Quick ratio
1.003
Long term debt to equity
8.428
Total debt to equity
8.502
Dividend payout ratio (TTM)
8.61%
Interest coverage (TTM)
2.59%
Profitability
EBITDA (TTM)
1,564
Gross margin (TTM)
53.40%
Net profit margin (TTM)
3.41%
Operating margin (TTM)
19.75%
Effective tax rate (TTM)
57.43%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
5.67%
Return on equity (TTM)
24.04%
Valuation
Price to earnings (TTM)
17.329
Price to revenue (TTM)
0.585
Price to book
3.59
Price to tangible book (TTM)
-0.85
Price to free cash flow (TTM)
8.256
Free cash flow yield (TTM)
12.11%
Free cash flow per share (TTM)
1.664
Dividend yield (TTM)
0.58%
Forward dividend yield
0.58%
Growth
Revenue change (TTM)
-2.45%
Earnings per share change (TTM)
-70.50%
3-year revenue growth (CAGR)
-0.22%
3-year earnings per share growth (CAGR)
-35.47%
3-year dividend per share growth (CAGR)
-58.51%
What the Analysts think about Organon
Analyst ratings (Buy, Hold, Sell) for Organon stock.
Analyst projections of the future price of Organon stock.
Bulls say / Bears say
Sun Pharma has agreed to buy Organon for $14 a share in cash, offering shareholders a defined takeout price if the deal closes. The acquisition is expected to close in early 2027. (Longbridge)
Biosimilars revenue rose 23% in the first quarter, helped by stronger Hadlima demand and contributions from newer products. This growing portfolio could help offset weakness elsewhere. (Organon)
The FDA expanded the approved uses of Organon’s biosimilar Tofidence, including for cytokine release syndrome. The wider label gives the product scope to serve more patients and support future sales. (Organon)
Sales momentum remains weak: first-quarter revenue fell 9% excluding currency effects, while Women’s Health revenue fell 19% and Nexplanon sales fell 21%. (Organon)
Organon had $8.55 billion of debt against $1.13 billion of cash at the end of June, with a 4.9% average borrowing rate. This heavy debt load leaves less room to absorb weaker trading or higher financing costs. (StockTitan)
Underlying earnings weakened even as reported net income rose: first-quarter adjusted net income fell to $188 million from $265 million, and adjusted earnings per share dropped to $0.71 from $1.02. That points to pressure on the profits available to service debt and fund the business. (Organon)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2026.
Organon Financial Performance
Revenues and expenses
Organon Earnings Performance
Company profitability
Upcoming events
No upcoming events
Organon News
AllArticlesVideos
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Business Wire1 month ago
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
Business Wire2 months ago
New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
Business Wire3 months ago
Funds containing Organon
AllUSDGBPEUR
Fund name | Fund size | $OGN weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.21% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.21% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.16% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.09% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.